DEPEMOKIMAB

Information current as at: 1 June 2026

PBAC meeting date: July 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Exdensur®
Form and strength:: Solution for subcutaneous injection 100 mg in 1 mL
Submission sponsor:: GLAXOSMITHKLINE AUSTRALIA PTY LTD
Condition/indication: (therapeutic use): Uncontrolled severe eosinophilic asthma
Listing requested:: To request listing of depemokimab for the treatment of uncontrolled severe eosinophilic asthma in patients aged 12 years or older with a blood eosinophil count greater than or equal to 300 cells per microlitre in the last 12 months, or with a blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months.
Funding program:: PBS Section 100 (Highly Specialised Drugs Program)
Request authority level:: Authority Required (Written) for initial treatment Authority Required (STREAMLINED) for continuing treatment
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: July 2026 PBAC meeting
Opportunity for consumer comment:: Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

1222

Page last updated

31 May 2026

v.9.19